Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 409
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT02758665 | Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL | ||
| NCT06663098 | Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC). | ||
| NCT00895206 | Individually Adapted Immunosuppression in de Novo Renal Transplantation Based on Immune Function Monitoring: a Prospective Randomised Study | ||
| NCT05293015 | NP-Supported Multidisciplinary Diabetes Management During Perioperative Period | ||
| NCT00774462 | Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia Gravis | ||
| NCT04993274 | Sensitivity of Motor Assessment in MS - a Prospective Cohort Study | ||
| NCT05825625 | NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing | ||
| NCT01683175 | Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation | ||
| NCT04490044 | Under and Over Rehabilitation Study | ||
| NCT01457144 | Study of Mantle Cell Lymphoma Treatment by RiBVD | ||
| NCT01015352 | Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA) | ||
| NCT05765084 | Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma | ||
| NCT06067061 | "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer | ||
| NCT05017142 | Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD) | ||
| NCT00316420 | Gemcitabine and Capecitabine in Patients With Advanced Pancreatic Cancer | ||
| NCT01259817 | Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) | ||
| NCT00901524 | ANRS HC20 Effectiveness of an Optimized Anti HCV PegIFN-alpha2a + Ribavirin on Sustained Virological Response in Patients With HCV Genotype 1 and 4 Non Responders and Co-infected With HIV | ||
| NCT00484328 | Ribavirin, Its Dosing Regime | ||
| NCT03275311 | Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008 | ||
| NCT01953458 | Therapeutic Option for Hepatitis B and C: a French Cohort | ||
| NCT00453362 | A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib | ||
| NCT04144270 | The Importance of Muscle Function in Patients With Disseminated Bladder Cancer | ||
| NCT05050214 | Obinutuzumab in Primary MN | ||
| NCT00217152 | A Kidney Transplant Study to Look at the Effects of Taking Fixed Doses of CellCept Versus Taking Doses of CellCept Based on the Concentration of CellCept in the Blood When Taking Full or Reduced Dose Calcineurin Inhibitors | ||
| NCT00438152 | Lopinavir Capsules to Kaletra or Invirase Tablets | ||
| NCT01640405 | Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells | ||
| NCT03697850 | Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy | ||
| NCT04557813 | Registry for Molecular Testing, Treatment and Outcome of Patients With Solid Tumors Harboring a NTRK Gene Fusion | ||
| NCT00275535 | The Comparison of Tacrolimus and Sirolimus Immunosuppression Based Drug Regimens in Kidney Transplant Recipients | ||
| NCT01329952 | Reinfection and Long Term Outcomes in Intravenous Drug Users (IVDUs) After Hepatitis C Treatment | ||
| NCT00433589 | Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes | ||
| NCT03322865 | Obinutuzumab in Marginal Zone Lymphoma | ||
| NCT01686321 | Rituximab and Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients With Aggressive B-cell Lymphoma | ||
| NCT07542678 | Double-T - Improving Outcomes in High-risk 2nd Line Relapsed/Refractory Large B-Cell Lymphoma Patients Eligible for CAR-T-cell Therapy With a Glofitamab-based Induction and Consolidation Concept | ||
| NCT04253561 | Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients | ||
| NCT00275665 | The Study is Being Done to See if Taking the Drug Valganciclovir Can Prevent CMV Infection. | ||
| NCT00394992 | Adjuvant Xeloda Plus Eloxatin +/- Avastin After Radical Resection of Liver Metastasis of Colorectal Cancer | ||
| NCT02569736 | Characterization of the Effect of Tocilizumab in Vivo and in Vitro on T Follicular Helper Cells in Rheumatoid Arthritis Patients and Consequence on B Cells Maturation | ||
| NCT02120911 | Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma | ||
| NCT01306409 | Neocytolysis in the Treatment of Renal Anemia With Erythropoieses Stimulating Agents (ESA) | ||
| NCT01745965 | A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol. | ||
| NCT05689671 | Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma | ||
| NCT03197805 | Assessment of the Impact of RNA Genomic Profile on Treatment Decision-making in HER2 Equivocal Breast Cancer Patients | ||
| NCT00219739 | STI571 ProspectIve RandomIzed Trial: SPIRIT | ||
| NCT02626845 | Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis | ||
| NCT02389842 | PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib | ||
| NCT00193609 | Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site | ||
| NCT06068985 | Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade | ||
| NCT00144976 | Study of Biological Effect of Tarceva (OSI-774) for Patients Stricken by ENT Epidermoid Carcinoma | ||
| NCT04939662 | Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects |
